Blüher, Matthias http://orcid.org/0000-0003-0208-2065
Rosenstock, Julio http://orcid.org/0000-0001-8324-3275
Hoefler, Josef
Manuel, Raymond
Hennige, Anita M. http://orcid.org/0000-0002-5149-4966
Funding for this research was provided by:
Boehringer Ingelheim
Universität Leipzig
Article History
Received: 18 May 2023
Accepted: 17 August 2023
First Online: 14 December 2023
Change Date: 13 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00125-024-06095-7
Acknowledgements
: Medical writing support in the preparation of this manuscript was provided by Susie Eaton, MBio, and Tom Priddle, DPhil, of OPEN Health Communications (UK), funded by Boehringer Ingelheim. We thank all the participants and study investigators for their participation in this trial. Survodutide was co-invented with Zealand Pharma. Data from some sections of this article were previously presented at the 58th EASD Annual Meeting in 2022 and at ObesityWeek 2022.
: To ensure independent interpretation of clinical study results and enable authors to fulfil their role and obligations under the ICMJE criteria, Boehringer Ingelheim grants all external authors access to relevant clinical study data. In adherence with the Boehringer Ingelheim Policy on Transparency and Publication of Clinical Study Data, scientific and medical researchers can request access to clinical study data after publication of the primary manuscript and secondary analyses in peer-reviewed journals and regulatory and reimbursement activities are completed, normally within 1 year after the marketing application has been granted by major regulatory authorities. Researchers should use the ExternalRef removed link to request access to study data and visit ExternalRef removed for further information.
: Open Access funding enabled and organized by Projekt DEAL. Under the terms of the glucagon/GLP-1 licensing agreement, Boehringer Ingelheim funds all research, development and commercialisation activities. Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany) funded the study and had a role in study design, data collection, data analysis and data interpretation and provided support for editorial aspects of this report.
: RM is an employee of Boehringer Ingelheim Pharmaceuticals, Inc. AMH is an employee of Boehringer Ingelheim International GmbH. JH is an employee of Staburo GmbH, on behalf on Boehringer Ingelheim Pharma GmbH & Co. JR has served on advisory panels for Applied Therapeutics, Boehringer Ingelheim, Eli Lilly, Hanmi, Intarcia, Novo Nordisk, Oramed, Sanofi, Structure Therapeutics, Terns Pharma and Zealand; has received honoraria for lectures sponsored by Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi; and has received research support from Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Genentech, GlaxoSmithKline, Hanmi, Intarcia, Lexicon, Merck, Novartis, Novo Nordisk, Oramed, Pfizer and Sanofi. MB received honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, Pfizer and Sanofi; and has participated on a data safety monitoring board/advisory board for Boehringer Ingelheim.
: AMH designed the study, interpreted the data and contributed to the discussion and development of the manuscript. MB and JR contributed to the conduct of the study, participated blindly in the safety monitoring committee, interpreted the data and contributed to the development of the manuscript. RM was the clinical trial lead in coordinating all activities in the conduct of the study. JH planned and conducted the statistical analyses and supported the design of the study and interpretation of data. All authors had full access to all of the data in the study, drafted the work or revised it critically for important intellectual content, and approved the final version of the manuscript and accept responsibility to submit for publication. AMH is the guarantor of this work.